Latest Healthcare News

Embelton Limited (ASX:EMB) grew revenue, profit and operating cash flow in FY2026 despite subdued residential construction, while maintaining its 35-cent fully franked annual dividend. The flooring and engineering group is leaning further into infrastructure, data centres, healthcare and other commercial work, although its near-term contracting pipeline remains modest.

Paradigm Biopharmaceuticals will keep its ASX securities suspended until at least 30 September while it reviews interim Phase 3 data and assesses the operational and financial consequences. The company also remains in discussions with Obsidian Global GP, LLC, but has not disclosed the trial results or their direction.

Enlitic has secured a US$806,000 contract to migrate 10.6 million medical imaging studies for University of Michigan Health-Sparrow. The project also gives its Ensight platform a first active integration with Sectra’s enterprise imaging environment.

Marlin Global’s portfolio fell 6.3% before fees and tax in FY26 while its benchmark gained 30.5%, producing a NZ$17.3 million net loss. The Fisher Funds-managed vehicle is responding with broader sector coverage, faster portfolio turnover and an expanded research team.

Barramundi Limited (NZX:BRM) has reported the worst performance in its 20-year history, with a NZ$42.9 million net loss and a 17.0% fall in gross portfolio performance. The board is reviewing Fisher Funds’ management performance just weeks before its five-year agreement comes up for renewal.

Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.

Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.

Betashares’ newly launched FTSE Global Infrastructure Shares Currency Hedged ETF reported $1.204 billion in profit and $8.08 billion in net assets for its first reporting year. The audited results also show strong gains across several established funds, alongside sharp post-year-end NAV movements in energy and gold miners.

HealthCo Healthcare and Wellness REIT (ASX: HCW) reported a $49.7 million FY26 statutory loss, suspended distributions and received an unmodified audit opinion that nevertheless highlighted a material uncertainty over its ability to continue as a going concern. The key unresolved issue is the transfer of 10 Healthscope hospitals to alternative operators.

Ramsay Health Care delivered stronger FY26 earnings, a higher fully franked dividend and improved Funding Group leverage as it prepares to separate Ramsay Santé. The proposed demerger remains conditional, but the company has set a clear timetable for the next phase of its portfolio reshaping.

GWA Group delivered its third consecutive year of volume growth in FY26, lifting revenue, normalised EBIT and its fully franked dividend despite weak housing and renovation conditions. The trade-off was a sharp decline in operating cash flow and higher net debt following inventory purchases and a $25 million share buyback.

Sonic Healthcare delivered a strong FY2026, with underlying net profit up 17% to A$621 million and dividends rising to A$1.08 per share. The next test is whether US efficiencies, LADR synergies and organic growth can offset Swiss fee cuts, a delayed UK contract ramp-up and heavier investment demands.